Overview

OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients: a Randomized Factorial Controlled Strategy Trial

Status:
Not yet recruiting

Trial end date:
2025-01-01

Target enrollment:

Participant gender:

Summary

The overall purpose of the trial is to evaluate the efficacy and safety of possible combination antiviral therapy (mAbs (T/C)∞ + nirmatrelvir/r) versus the reference monotherapy (nirmatrelvir/r alone) and to assess the efficacy and safety of increasing the nirmatrelvir/r course from 5- to 10 days in immunocompromised patients diagnosed with asymptomatic or mild to moderate COVID-19.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

ANRS, Emerging Infectious Diseases

Collaborator:

University Hospital, Geneva

Treatments:

Ritonavir